Sandra A Johnson
Overview
Explore the profile of Sandra A Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
365
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Johnson S, Simms I, Sheringham J, Bickler G, Bennett C, Hall R, et al.
Sex Transm Infect
. 2010 May;
86(3):217-21.
PMID: 20460264
Background: England's National Chlamydia Screening Programme (NCSP) provides opportunistic testing for under 25 year-olds in healthcare and non-healthcare settings. The authors aimed to explore relationships between coverage and positivity in...
12.
Antill Y, Mitchell G, Johnson S, Devereux L, Milner A, Di Iulio J, et al.
Cancer Epidemiol Biomarkers Prev
. 2010 Jan;
19(1):265-74.
PMID: 20056647
Purpose: Genomic alterations (including gene hypermethylation) are likely to precede the phenotypic changes associated with breast tumorigenesis. From a prospective collection of ductal lavage (DL) samples from women with a...
13.
Williams L, Choong D, Johnson S, Campbell I
Clin Cancer Res
. 2006 Dec;
12(23):6967-72.
PMID: 17145815
Purpose: Germ-line variants in CHEK2 have been associated with increased breast, thyroid, prostate, kidney, and colorectal cancer risk; however, the prevalence of somatic inactivation of CHEK2 in common cancer types...
14.
Antill Y, Mitchell G, Johnson S, Devereux L, Milner A, Phillips K, et al.
Cancer Epidemiol Biomarkers Prev
. 2006 Jul;
15(7):1396-8.
PMID: 16835342
Background: Loss of heterozygosity (LOH) in breast ductal lavage (DL) fluid has been reported to be a potential biomarker of malignant change. Interpretation of LOH is reliant on sufficient quality...
15.
Morgan T, Atkins G, Trivett M, Johnson S, Kansara M, Schlicht S, et al.
Am J Pathol
. 2005 Jun;
167(1):117-28.
PMID: 15972958
Giant cell tumor of bone (GCT) is a generally benign, osteolytic neoplasm comprising stromal cells and osteoclast-like giant cells. The osteoclastic cells, which cause bony destruction, are thought to be...
16.
Thomas D, Johnson S, Sims N, Trivett M, Slavin J, Rubin B, et al.
J Cell Biol
. 2004 Dec;
167(5):925-34.
PMID: 15583032
The molecular basis for the inverse relationship between differentiation and tumorigenesis is unknown. The function of runx2, a master regulator of osteoblast differentiation belonging to the runt family of tumor...
17.
Chin S, Johnson S, Quinn J, Mirosavljevic D, Price J, Dudley A, et al.
Biochem Biophys Res Commun
. 2003 Jul;
307(4):1051-8.
PMID: 12878218
TGF-beta increases bone resorption in vivo and greatly increases osteoclast formation stimulated by receptor activator of NF-kappaB ligand (RANKL) in vitro. TGF-beta does not independently affect the differentiation state of...